1. Scrip
  2. >>Therapy Areas
  3. >>Sensory

Kala Hopes To Stride Into Dry Eye Market This Year

 
• By Jo Shorthouse

Kala Pharmaceuticals is hoping to shake up the dry eye market with a NDA filing this year for its steroid eye drop KPI-121 0.25%.

Vision
KPI-121 0.25% uses mucus-penetrating particle technology

Kala Pharmaceuticals Inc. is planning to file a new drug application in the US for what it hopes will become the first FDA-approved treatment for short-term dry eye disease, specifically dry eye flares. The $1.7bn dry eye market is currently dominated by Shire PLC and Allergan PLC, with Xiidra (lifitegrast) and Restasis (cyclosporine ophthalmic emulsion) respectively.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Sensory

More from Therapy Areas

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.